首页> 外文期刊>World Journal of Gastroenterology >Avidin-biotin system pretargeting radioimmunoimaging and radioimmunotherapy and its application in mouse model of human colon carcinoma
【24h】

Avidin-biotin system pretargeting radioimmunoimaging and radioimmunotherapy and its application in mouse model of human colon carcinoma

机译:靶向放射免疫成像和放射免疫疗法的抗生物素蛋白-生物素系统及其在人结肠癌小鼠模型中的应用

获取原文
获取原文并翻译 | 示例
       

摘要

AIM: To evaluate the multi-step pretargeting radioimmunoimaging (RII) and radioimmunotherapy (RIT) in nude mice bearing human colon carcinoma with avidin-biotin system labeled with ~(153)Sm. METHODS: Two- and three-step strategies for avidin-biotin system pretargeting techniques were established. In a three-step procedure, human colon carcinoma bearing nude mice were first injected with biotinylated monoclonal antibody (McAb-Bt) followed by cold avidin (Av) 48 h later and then ~(153)Sm-DB_2 24 h thereafter; whereas the two-step procedure consisted of injection of ~(153)Sm-SA 48 h after pretargeting with biotinylated anti-CEA monoclonal antibody (CEA McAb-Bt). SPECT imaging and biodistribution were performed at 4, 24, 48, or 72 h after injection of ~(153)Sm-labeled compounds. Five groups of nude mice subcutaneously grafted with human colon carcinoma were treated 3 d after grafting. One group received the injection with 100 μg CEA McAb-Bt followed by cold avidin (80 μg) after 2 d and 11.1 MBq ~(153)Sm-DB_2 after 1 d. Four control groups were treated respectively with 11.1 MBq ~(153)Sm-CEA McAb, 11.1 MBq ~(153)Sm-nmIgG, 11.1 MBq ~(153)Sm-DB_2, 100 μL normal saline. Toxicity was evaluated by changes of leukocyte count, and the efficacy by variation in tumor volume. Histological analyses of tumors were performed. RESULTS: The three-step procedure allowed faster blood clearance and yielded higher tumor blood ratios (5.76 at 4 h and 12.94 at 24 h) of the ~(153)Sm-DB_2. The tumor was clearly visualized at 4 h in γ-imaging after the injection of ~(153)Sm-DB_2, while a significant accumulation of ~(153)Sm-SA in the tumor was observed only 24 h after the injection and tumor blood ratios at 4 and 24 h were 1.00 and 2.03, respectively, in the two-step procedure. Pretargeting RIT and ~(153)Sm-CEA McAb had a strong tumor-inhibiting effect. The tumor inhibitory rate was 80.67% and 78.44%, respectively, five weeks after therapy. Histopathological evidence also indicated radioactive damage in tumor tissues as necrosis of tumor cells, while in the other organs such as liver and kidney no radioactive damage was observed. Leukocyte counts showed significant decrease after treatment in groups of ~(153)Sm-CEA McAb and ~(153)Sm-nmIgG. CONCLUSION: The two kinds of pretargeting strategies can elevate the target-to-nontarget ratio, decrease the blood background and shorten the imaging time compared to ~(153)Sm-CEA McAb. Three-step pretargeting RIT is as efficient as ~(153)Sm-CEA McAb, but markedly less toxic. This study provides experimental evidence for the clinical application of pretargeting RII and RIT.
机译:目的:评估带有人结肠癌的裸鼠的多步骤预靶向放射免疫成像(RII)和放射免疫疗法(RIT),并用〜(153)Sm标记的抗生物素蛋白-生物素系统。方法:建立了抗生物素蛋白-生物素系统预靶向技术的两步和三步策略。在三步过程中,先在人结肠癌裸鼠中注射生物素化单克隆抗体(McAb-Bt),然后在48小时后注射抗生物素蛋白(Av),然后在24小时后注射〜(153)Sm-DB_2。而分两步进行的程序包括在用生物素化抗CEA单克隆抗体(CEA McAb-Bt)预先靶向后48小时内注射〜(153)Sm-SA。在注射〜(153)Sm标记的化合物后的4、24、48或72 h进行SPECT成像和生物分布。在移植后3天对五组皮下移植人结肠癌的裸鼠进行治疗。一组接受注射100μgCEA McAb-Bt,然后于2 d注射冷抗生物素蛋白(80μg),并于1 d接受11.1 MBq〜(153)Sm-DB_2注射。四个对照组分别用11.1 MBq〜(153)Sm-CEA单克隆抗体,11.1 MBq〜(153)Sm-nmIgG,11.1 MBq〜(153)Sm-DB_2、100μL生理盐水处理。通过白细胞计数的变化评估毒性,通过肿瘤体积的变化评估疗效。进行肿瘤的组织学分析。结果:三步程序允许更快的血液清除,并产生更高的〜(153)Sm-DB_2肿瘤血液比率(4小时时为5.76,24小时时为12.94)。注射〜(153)Sm-DB_2后第4小时在γ成像中清晰可见肿瘤,而注射后第24小时和肿瘤血液中观察到〜(153)Sm-SA在肿瘤中的大量积累。在两步程序中,第4和第24小时的比率分别为1.00和2.03。预靶向RIT和〜(153)Sm-CEA McAb具有很强的抑瘤作用。治疗5周后,肿瘤抑制率分别为80.67%和78.44%。组织病理学证据还表明,肿瘤组织中的放射性损伤为肿瘤细胞坏死,而在其他器官如肝和肾中,未观察到放射性损伤。 〜(153)Sm-CEA McAb和〜(153)Sm-nmIgG组中治疗后白细胞计数显着下降。结论:与〜(153)Sm-CEA McAb相比,两种预靶向策略可以提高靶与非靶的比率,降低血液背景并缩短成像时间。三步预靶向RIT与〜(153)Sm-CEA McAb一样有效,但毒性明显较低。这项研究为预靶向RII和RIT的临床应用提供了实验证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号